



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref. No.: ADL/SE/2017-2018

Date: 14th February, 2018

To, Department of corporate service, BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. <u>BSE CODE - 524348</u> BSE ID - AARTIDRUGS	To, National Stock Exchange of India Limited, "Exchange Plaza", Bandra - Kurla Complex, Bandra (E), Mumbai - 400051. <u>NSE SYMBOL: AARTIDRUGS</u>
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 14th February, 2018.

This is for your information and records.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited

Adhish P. Patil
Chief Financial Officer





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Press release for Dec'17:

December quarter has shown good demand growth both in domestic, with a value growth of 22%, as well as global markets with a value growth of 11.4%. Formulation business grew by around 5.5% and is expected to grow further due to higher exports. Consolidated net sales for the quarter ended Dec'17 grew by 15.8%

Consolidated EBITDA for the quarter ended Dec'17 is 54.06 crores, up by 25.3% and Consolidated Profit after tax for the quarter ended Dec'17 is 23.33 crores, up by 30.7%. Operating margins were good due to lower raw material costs and better operational efficiency. Company has strategically increased its inventories leading to slight increase in working capital, which should come down by end of Mar'18. Debt/Equity ratio was 1.21 as of Dec'17, which should reduce in future.

Company had USFDA re-inspection in the month of December'17. There were 5 observations out of which 3 are already complied with and for rest of the 2 observations company has a deadline of 6 months to reply. Europe and Southeast Asia will continue to be key growth drivers for the company in exports. Company recently completed the expansion of its multipurpose facility in Tarapur, which is intended for the API exports to European markets.

For Aarti Drugs Limited

Adhish P. Patil
Chief Financial Officer

